SUMMARY We have studied the effect of the immunosuppressive agent cyclosporin on collagen induced arthritis in mice. Cyclosporin, when given prophylactically, was capable of suppressing the development of collagen induced arthritis and the immunological response to native type II collagen in a dose dependent manner. Furthermore, treatment with cyclosporin, started on the same day as the booster injection with type II collagen, also resulted in inhibition of development of arthritis and of immunity to collagen. These findings suggest that the time of a booster injection, three weeks after the initial immunisation, might be still within the induction phase of arthritis since reinoculation is required to produce a high incidence of arthritis in mice. In addition, therapeutic treatment with cyclosporin did not affect the clinical course of the disease or the immune response to collagen. 
Immunisation with native type II collagen induces inflammatory polyarthritis and immunity to collagen in rats and susceptible strains of mice.-The disease, which has been shown to have similarities to human rheumatoid arthritis in many respects,7 can be transferred by immune sera from arthritic rats to naive mice8 and rats.9 Furthermore, we reported previously that a serum concentrate from arthritic rats is capable of inducing arthritis in cyclosporin treated, type II collagen tolerant rats"' and congenitally athymic nude rats. 1 1 These findings suggest that arthritis in rats and mice might be caused by similar mechanisms,8 and that arthritis could be induced by humoral immunity in the absence of cell mediated immunity. " Although pathogenetic mechanisms and the histopathology of collagen induced arthritis in mice are similar to those seen in rats, 3 5there are definite discrepancies in the immune response to collagen between these two species.3 5 achieved by treating the animals daily with 100 mg/kg/day of cyclosporin, whereas no clear effects were produced by 25 mg/kg/day of the drug. The effects were accompanied by the inhibition of REI to collagen measured on day 48 and of anti-type II collagen antibody production measured on days 21 and 47. These findings are in accord with our previous report, which suggested that helper T cell function is mandatory for the production of antitype II collagen antibody. '5 Effect from the day of a booster injection of type II collagen Mice were injected daily with cyclosporin at a dose of 100 mg/kg for two weeks from the day of a booster injection. It is apparent from a number of in vitro experiments that cyclosporin exerts its effect at a very early stage of T cell differentiation.2S29 Cyclosporin, however, again produced statistically significant suppression of the development of arthritis (Table 2) . Moreover, serum antibodies to collagen measured on day 47 and REI to collagen measured on day 48 in cyclosporin treated mice were significantly reduced, though no difference was observed in serum antibodies to collagen measured at the time of a booster injection. A small number of cyclosporin treated animals developed disease, and in those that did the disease was less severe. The onset of the disease in cyclosporin treated mice, however, was not delayed.
Effect on the established disease The response of the established disease to cyclosporin treatment was studied. Only arthritic mice received daily cyclosporin therapy for 10 days beginning 35 days after primary immunisation. Cyclosporin did not affect the course of the disease (Fig. 2) , nor did its administration alter the immunological response to collagen in this regimen (Table  3) .
We did not observe a significant decrease in weight or any other toxic signs in animals receiving 
